Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy) phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor α-converting enzyme inhibitor, on the disposition of methotrexate: A transporter-based drug-drug interaction case study

Drug Metabolism and Disposition

Volumn 35, Issue 6, 2007, Pages 835-840

  Luo, Gang ^a   Garner, C Edwin ^b   Xiong, Hao ^c   Hu, Hanbo ^d   Richards, Lauren E ^e   Brouwer, Kim L R ^c   Duan, Jingwu ^a   Decicco, Carl P ^a   Maduskuie, Thomas ^a   Shen, Helen ^f   Lee, Frank W ^g   Gan, Liang Shang ^d  

^a BRISTOL MYERS SQUIBB   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Quest Pharmaceutical Services   (United States)

^g MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 AMINO 3 [4 (2 METHYLQUINOLIN 4 YLMETHOXY)PHENYL] 2 OXOPYRROLIDIN 1 YL] N HYDROXY 4 METHYLPENTANAMIDE; DPC 333; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; KIDNEY CLEARANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT;

ADAM PROTEINS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; DOGS; DRUG INTERACTIONS; HUMANS; KIDNEY; LIVER; METHOTREXATE; QUINOLINES; RATS; RATS, WISTAR;

CANIS FAMILIARIS; RATTUS; RATTUS NORVEGICUS;

EID: 34249023089     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013946     Document Type: Article

References (40)

1. Akita H, Suzuki H, and Sugiyama Y (2001) Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver. Pharm Res (NY) 18:1119-1125.
2. Birn H, Spiegelstein O, Christensen E, and Finnell R (2005) Renal tubular reabsorption of folate mediated by folate binding protein 1. J Am Soc Nephrol 16:608-615.
3. Borst P, Evers R, Kool M, and Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
4. Bressolle F, Bologna C, Kinowski J, Sany J, and Combe B (1998) Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 57:110-113.
5. Brouwer KLR and Thurman RG (1996) Isolated persfused liver, in Models for Assessing Drug Absorption and Metabolism (Borchardt RT, Smith PL, and Wilson G eds) pp 161-186. Plenum Press, New York.
6. Chladek J, Martinkova J, Simkova M, Vaneckova J, Koudelkova V, and Nozickova M (1998) Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 53:437-444.
7. Chladek J, Martinkova J, and Sispera L (1997) An in vitro study on methotrexate hydroxylation in rat and human liver. Physiol Res 46:371-379.
8. Furst D (1995) Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 34 (Suppl 2):20-25.
9. Gerk P and Vore M (2002) Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 302:407-415.
10. Henderson E, Adamson R, Denham C, and Oliverio V (1965a) The metabolic fate of tritiated methotrexate. I. Absorption, excretion, and distribution in mice, rats, dogs and monkeys. Cancer Res 25:1008-1017.
11. Henderson E, Adamson R, and Oliverio V (1965b) The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res 25:1018-1024.
12. Hirohashi T, Suzuki H, and Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 274:15181-15185.
13. Huang K, Wenczak B, and Liu Y (1979) Renal tubular transport of methotrexate in the rhesus monkey and dog. Cancer Res 39:4843-4848.
14. Hulot J, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez C, Hatem S, Deray G, et al. (2005) A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 15:277-285.
15. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, and Sugiyama Y (1997) Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Physiol 272:G16-G22.
16. Iven H and Brasch H (1988) The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits. Cancer Chemother Pharmacol 21:337-342.
17. Iven H and Brasch H (1990) Cephalosporins increase the renal clearance of methotrexate and 7-hydroxymethotrexate in rabbits. Cancer Chemother Pharmacol 26:139-143.
18. Iyanagi T, Emi Y, and Ikushiro S (1998) Biochemical and molecular aspects of genetic disorders of bilirubin metabolism. Biochim Biophys Acta 1407:173-184.
19. Jansen PL, Peters WH, and Lamers WH (1985) Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 5:573-579.
20. Kool M, van der Linden M, de Haas M, Scheffer G, de Vree J, Smith A, Jansen G, Peters G, Ponne N, Scheper R, et al. (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6914-6919.
21. Lefebvre H, Laroute V, Alvinerie M, Schneider M, Vinclair P, Braun J, and Toutain P (1997) The effect of experimental renal failure on tolfenamic acid disposition in the dog. Biopharm Drug Dispos 18:79-91.
22. Liegler D, Henderson E, Hahn M, and Oliverio V (1969) The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 10:849-857.
23. Lui C, Lee M, and Chiou W (1985) Urinary pH and urine flow independent renal clearance of methotrexate in dogs. J Pharmacokinet Biopharm 13:159-171.
24. Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, and Sugiyama Y (1997) Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 57:3506-3510.
25. Nuernberg B, Koehnke R, Solsky M, Hoffman J, and Furst D (1990) Biliary elimination of low-dose methotrexate in humans. Arthritis Rheum 33:898-902.
26. Paulusma C, Bosma P, Zaman G, Bakker C, Otter M, Scheffer G, Scheper R, Borst P, and Oude Elferink R (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (Wash DC) 271:1126-1128.
27. Rajgopal A, Sierra E, Zhao R, and Goldman I (2001) Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am J Physiol 281:C1579-C1586.
28. Saito H, Masuda S, and Inui K (1996) Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J Biol Chem 271:20719-20725.
29. Schnabel A and Gross WL (1994) Low-dose methotrexate in rheumatic diseases - efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 23:310-327.
30. Seideman P, Beck O, Eksborg S, and Wennberg M (1993) The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 35:409-412.
31. Statkevich P, Fournier D, and Sweeney K (1993) Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. J Pharmacol Exp Ther 265:1118-1124.
32. Steinberg S, Campbell C, Bleyer W, and Hillman R (1982) Enterohepatic circulation of methotrexate in rats in vivo. Cancer Res 42:1279-1282.
33. Ueda K, Kato Y, Komatsu K, and Sugiyama Y (2001) Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther 297:1036- 1043.
34. Uwai Y, Okuda M, Takami K, Hashimoto Y, and Inui K (1998) Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett 438:321-324.
35. Uwai Y, Saito H, and Inui K (2000) Interaction between methotrexate and nonsteroidal antiinflammatory drugs in organic anion transporter. Eur J Pharmacol 409:31-36.
36. Van Aubel R, Masereeuw R, and Russel F (2000) Molecular pharmacology of renal organic anion transporters. Am J Physiol 279:F216-F232.
37. Weinblatt M, Coblyn J, Fox D, Fraser P, Holdsworth D, Glass D, and Trentham D (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818-822.
38. Williams W and Huang K (1982) Renal tubular transport of folic acid and methotrexate in the monkey. Am J Physiol 242:F484-F490.
39. Xiong H, Suzuki H, Sugiyama Y, Meier P, Pollack G, and Brouwer KLR (2002) Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 30:962-969.
40. Xiong H, Turner K, Ward E, Jansen P, and Brouwer KLR (2000) Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J Pharmacol Exp Ther 295:512-518.